臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

???ui.leftmenu.abouttair???
	???ui.leftmenu.explanation???

???ui.leftmenu.bartitle???
	Repositories
	Author
	Title
	Date
	???ui.leftmenu.statisticschart???
	???ui.leftmenu.realtimefacts???
	???ui.leftmenu.trend???

???index.news???
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

???ui.leftmenu.copyrighttitle???
	???ui.leftmenu.copyrightpublisher???
	???ui.leftmenu.copyrightconference???

???ui.leftmenu.link???
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"kao j h"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1???	???jsp.browse.items-by-author.order2???

Showing items 836-860 of 1534 (62 Page(s) Totally)
<< < 29 30 31 32 33 34 35 36 37 38 > >>
View [10|25|50] records per page

Institution	Date	Title	Author
臺大學術典藏	2021-03-09T01:47:39Z	Clinical significance of circulating miR-122 in patients with dual chronic hepatitis B and C virus infection	Cheng H.-R.; Kao J.-H.; Wu H.-L.; Tseng T.-C.; Liu C.-H.; Yang H.-C.; TUNG-HUNG SU; Chen P.-J.; Chen D.-S.; Liu C.-J.
臺大學術典藏	2021-03-09T01:47:39Z	Molecular mechanism and treatment of viral hepatitis-related liver fibrosis	TUNG-HUNG SU; Kao J.-H.; Liu C.-J.
臺大學術典藏	2021-03-09T01:47:38Z	HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients	Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU; Tseng T.-C.; Lin H.H.; Wang C.-C.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:38Z	Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir	Chen G.-Y.; TUNG-HUNG SU; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:38Z	Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B	Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; TUNG-HUNG SU; Liu C.-J.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:38Z	Improving clinical outcomes of chronic hepatitis B virus infection	TUNG-HUNG SU; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:37Z	Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition	TUNG-HUNG SU; Shiau C.-W.; Jao P.; Liu C.-H.; Liu C.-J.; Tai W.-T.; Jeng Y.-M.; Yang H.-C.; Tseng T.-C.; Huang H.-P.; Cheng H.-R.; Chen P.-J.; Chen K.-F.; Kao J.-H.; Chen D.-S.
臺大學術典藏	2021-03-09T01:47:37Z	Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping	Liu C.-H.; Liang C.-C.; Liu C.-J.; Lin C.-L.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:37Z	Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers with genotype C infection	Tseng T.-C.; Liu C.-J.; Chen C.-L.; Yang W.-T.; Yang H.-C.; TUNG-HUNG SU; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:37Z	Advanced hepatic fibrosis and steatosis are associated with persistent alanine aminotransferase elevation in chronic hepatitis C patients negative for hepatitis C virus RNA during pegylated interferon plus ribavirin therapy	Liang C.-C.; Liu C.-H.; Chung C.-S.; Lin C.-K.; TUNG-HUNG SU; Yang H.-C.; Liu C.-J.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:36Z	Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-03-09T01:47:35Z	Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial	Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; Lee C.-Y.; Chen S.-I.; Yang S.-S.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:35Z	Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial	Liu C.-H.; Huang C.-F.; Liu C.-J.; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; TUNG-HUNG SU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L.
臺大學術典藏	2021-03-09T01:47:35Z	Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers	Tseng T.-C.; Liu C.-J.; Yang H.-C.; Chen C.-L.; Yang W.-T.; Tsai C.-S.; Kuo S.F.-T.; Verbree F.C.; TUNG-HUNG SU; Wang C.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:34Z	Peginterferon plus Ribavirin for HIV-infected Patients with Treatment-Naive Acute or Chronic HCV Infection in Taiwan: A Prospective Cohort Study	Liu C.-H.; Sheng W.-H.; Sun H.-Y.; Hsieh S.-M.; Lo Y.-C.; Liu C.-J.; TUNG-HUNG SU; Yang H.-C.; Liu W.-C.; Chen P.-J.; Chen D.-S.; Hung C.-C.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:34Z	Hepatitis C viral infection increases the risk of lymphoid-neoplasms: A population-based cohort study	TUNG-HUNG SU; Liu C.-J.; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:33Z	Hepatitis B surface antigen loss and hepatocellular carcinoma development in patients with dual hepatitis B and C infection	Yang W.-T.; Wu L.-W.; Tseng T.-C.; Chen C.-L.; Yang H.-C.; TUNG-HUNG SU; Wang C.-C.; Kuo S.F.-T.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Liu C.-J.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:33Z	Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan	Wang C.-C.; Lin C.-L.; Hsieh T.-Y.; Tseng K.-C.; Peng C.-Y.; TUNG-HUNG SU; Yang S.-S.; Hsu Y.-C.; Chen T.-M.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:32Z	Associated factors and clinical implications of serum aminotransferase elevation in scrub typhus	TUNG-HUNG SU; Liu C.-J.; Shu P.-Y.; Fu Y.-H.; Chang C.-H.; Jao P.; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:32Z	Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients	TUNG-HUNG SU; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; Hsu S.-J.; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; Tseng T.-C.; Chen C.-L.; Kao J.-H.; the C-TEAM study group; the Taiwan Liver Diseases Consortium
臺大學術典藏	2021-03-09T01:47:31Z	Unmet Needs in Clinical and Basic Hepatitis B Virus Research	TUNG-HUNG SU; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:31Z	High serum lipopolysaccharide-binding protein level in chronic hepatitis C viral infection is reduced by anti-viral treatments	Nien H.-C.; Hsu S.-J.; TUNG-HUNG SU; Yang P.-J.; Sheu J.-C.; Wang J.-T.; Chow L.-P.; Chen C.-L.; Kao J.-H.; Yang W.-S.
臺大學術典藏	2021-03-09T01:47:31Z	letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D	Kao C.-N.; TUNG-HUNG SU; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:30Z	Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in?chronic hepatitis B patients	TUNG-HUNG SU; Kao J.-H.
臺大學術典藏	2021-03-09T01:47:30Z	Surveillance of hepatocellular carcinoma by magnetic resonance imaging with liver-specific contrast	TUNG-HUNG SU; Kao J.-H.

Showing items 836-860 of 1534 (62 Page(s) Totally)
<< < 29 30 31 32 33 34 35 36 37 38 > >>
View [10|25|50] records per page

	English \| 正體中文 \| 简体中文 \| 2856565
	???header.visitor??? : 53388294 ???header.onlineuser??? : 1197 ???header.sponsordeclaration???